Cambridge Antibody's Underdog Story
622228
Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation.
101669
A new analysis finds that clinical trials of breast-cancer treatments by drugmakers show positive results far more often than non-industry trials. Why the difference?
581606
There's a hidden promise in these results.
725261
There's encouraging news about an enzyme replacement drug.
552158
It can be incredibly difficult for patients to ferret out studies of experimental drugs that offer hope to threat their disease. There is no comprehensive database of ongoing clinical trials, but specialists offer advice for the search:
14234
In a proof-of-concept study published this week in The Lancet, researchers report that GlaxoSmithKline&#39;s RTS,S/AS02A malaria vaccine candidate protected a significant percentage of children against uncomplicated malaria, infection, and even severe forms
434308
(12/06/04)âThe excitement that surrounded the approval in 2001 of Novartisâ rationally designed drug Gleevec, for the treatment chronic myelogenous leukemia (CML), was tinged by observations
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
424340
A small study shows its cancer treatment is comparable to others in terms of usefulness. Safety data is unknown.
640929
Shares of Cambridge-based Genzyme were up slightly today on news that the drug maker won approval for a drug to treat childhood leukemia.
97967
With doctors increasingly worried about "superbugs," deadly infections that can defeat most known drugs, a small Cambridge biotechnology firm has won $70 million in venture capital money to develop a powerful antibiotic from a microbe discovered in Haitian dirt.
301160
Transplants of insulin-making cells have not lived up to the promise they showed in an initial trial.
388185
Scientists believe they have found a way to spot which breast and ovarian cancers are likely to be aggressive. A team from the University of Texas, in the US, found cancer cells that overexpressed a particular protein were more likely to be fatal.
246371
Over the past six months, the usual strict hierarchies of the chip world have seen some rearranging. Perennial underdog Advanced Micro Devices (AMD:NYSE - news - research) has made impressive strides with
200497
The story of a tiny company that spent the little money it had on sponsoring a race car, sheds light on the market for small stocks that can fly below the radar for years.
514256
UK scientists have worked out a vaccine to stop Type-1 Diabetes for those with pre-disposition or recent diagonosis. The first human trial of the vaccine will start next year.
11870
Serono Inc., the US arm of the Swiss biotechnology giant, is looking at laboratory space in Cambridge for a possible expansion that would add to the growing number of industry heavyweights that have established research outposts in the hub of the Boston-area biotech cluster, according to several real estate brokers.